Compounds / Other / PNC-27

PNC-27

PNC-27 (p53-Derived Anti-Cancer Peptide)

OtherFDA: Not approved; preclinical research

Overview

Anti-cancer research compound. Preclinical: selective cancer cell destruction. Targets MDM-2 overexpression common in many cancers. No clinical trials completed.

Mechanism of Action

Peptide derived from p53 tumor suppressor protein. Selectively induces membrane disruption and necrosis in cancer cells overexpressing MDM-2. Targets cancer cell membranes without affecting normal cells.

Molecular Profile

Molecular weight

~3.5 kDa

Key Research Findings

Cancer cell membrane disruption; MDM-2 targeting; selective cancer cell death; no normal cell toxicity in preclinical data.

Published Research

J Surg Res (2008)

Bowne WB et al. Antitumor activity of the PNC-27 peptide

View source

Related Other Compounds

PT-141 Melanotan I Melanotan II Cystagen Dermorphin EPO

Clinical Guidance

Research data is not a treatment plan. If you are considering PNC-27, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.

Running PNC-27? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator · Full deep dive · Peptide fundamentals